Regulation of HIF by the von Hippel‐Lindau Tumour Suppressor: Implications for Cellular Oxygen Sensing
The DOI matches its Crossref record.
Abstract
Hypoxia‐inducible factor (HIF) is central in coordinating many of the transcriptional adaptations to hypoxia. Composed of a heterodimer of α and β subunits, the α subunit is rapidly degraded in normoxia, leading to inactivation of the hypoxic response. Many models for a molecular oxygen sensor regulating this system have been proposed, but an important finding has been the ability to mimic hypoxia by chelation or substitution of iron. A key insight has been the recognition that HIF‐ α is targeted for degradation by the ubiquitin‐proteasome pathway through binding to the von Hippel‐Lindau tumour suppressor protein (pVHL), which forms the recognition component of an E3 ubiquitin ligase complex leading to ubiquitylation of HIF‐ α. Importantly, the classical features of regulation by iron and oxygen availability are reflected in regulation of the HIF‐ α/p VHL interaction. It has recently been shown that HIF‐ α undergoes an iron‐ and oxygen‐dependent modification before it can interact with pVHL, and that this results in hydroxylation of at least one prolyl residue (HIF‐1 α, Pro 564). This modification is catalysed by an enzyme termed HIF‐prolyl hydroxylase (HIF‐PH), and compatible with all previously described prolyl‐4‐hydroxylases HIF‐PH also requires 2‐oxoglutarate as a cosubstrate. The key position of this hydroxylation in the degradation pathway of HIF‐ α, together with its requirement for molecular dioxygen as a co‐substrate, provides the potential for HIF‐PH to function directly as a cellular oxygen sensor. However, the ability of these enzyme(s) to account for the full range of physiological regulation displayed by the HIF system remains to be defined.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591
“Recent studies have uncovered the crucial role of the product of the von Hippel–Lindau (VHL) tumor suppressor gene in HIF-1-dependent hypoxic responses (reviewed in ref”
BackgroundVascular Endothelial Growth Factor: Basic Science and Clinical Progress
Ferrara, N. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0027 · Cited by 3,687
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625
“A link between the product of the von Hippel-Lindau (VHL) tumour-suppressor gene and HIF1-dependent responses has been established (for a review, see Ref”
BackgroundBevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy
Ferrara, N., Hillan, K. J., & Novotny, W. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.05.132 · Cited by 977
Guzy, R. D., & Schumacker, P. T. (2006) · Experimental Physiology · doi:10.1113/expphysiol.2006.033506 · Cited by 881
“Von Hippel-Lindau disease manifests by the development of haemangioblastomas and renal clear cell carcinomas that are highly vascular and exhibit high levels of HIF activation (Mole et al. 2001).”
Background
Metadata
- Authors
- Mole, D. R., Maxwell, P. H., Pugh, C. W., & Ratcliffe, P. J.
- Venue
- IUBMB Life
- Publisher
- Wiley
- Published
- 2001-07
- Volume
- 52
- Issue
- 1
- Pages
- 43-47
- ISSN
- 1521-6543 (ISSN-L)
- 1521-6551
- OpenAlex
- W2021529165
- Cited by
- 116
- References
- 0
- FWCI
- 1.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Regulation of HIF by the von Hippel‐Lindau Tumour Suppressor: Implications for Cellular Oxygen Sensing. https://app.cochat.ai/papers/10.1080/15216540252774757
- The paper
- Mole, D. R., Maxwell, P. H., Pugh, C. W., & Ratcliffe, P. J. (2001). Regulation of HIF by the von Hippel‐Lindau Tumour Suppressor: Implications for Cellular Oxygen Sensing. IUBMB Life. https://doi.org/10.1080/15216540252774757
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.